Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were potent hits against a mouse ependymoma cell line, but their effectiveness against central nervous system tumors will depend on their ability to cross the blood-brain barrier and attain a sufficient exposure at the tumor. Among 3-hydroxy-3-methylglutaryl coenzyme A inhibitors that had activity in vitro, we prioritized simvastatin (SV) as the lead compound for preclinical pharmacokinetic studies based on its potential for central nervous system penetration as determined from in silico models. Furthermore, we performed systemic plasma disposition and cerebral microdialysis studies of SV (100 mg/kg, p.o.) in a murine model of ependymoma to characterize plasma and tumor extracellular fluid (tECF) pharmacokinetic properties. The murine dosage of SV (100 mg/kg, p.o.) was equivalent to the maximum tolerated dose in patients (7.5 mg/kg, p.o.) based on equivalent plasma exposure of simvastatin acid (SVA) between the two species. SV is rapidly metabolized in murine plasma with 15 times lower exposure compared with human plasma. SVA exposure in tECF was <33.8 ± 11.9 µg/l per hour, whereas the tumor to plasma partition coefficient of SVA was <0.084 ± 0.008. Compared with in vit...Continue Reading
References
Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P J CaseyJ E Buss
Sep 1, 1997·Journal of Neuro-oncology·T KikuchiT Abe
Jul 6, 2000·International Journal of Pharmaceutics·M FeherJ M Schmidt
Sep 10, 2003·Neurosurgical Review·Jan GliemrothA Jorge A Terzis
Nov 12, 2005·The Journal of Pharmacology and Experimental Therapeutics·Karin M ThelenDieter Lütjohann
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Mar 22, 2006·The Oncologist·Katja HindlerCharles D Collard
Jun 23, 2007·Nature Reviews. Drug Discovery·Panagiotis A KonstantinopoulosAthanasios G Papavassiliou
Dec 9, 2008·Journal of Neurosurgery·Courtney S McGuirePaul G Fisher
Mar 11, 2009·The Lancet Oncology·Thomas E MerchantRobert A Sanford
May 2, 2009·Journal of Pharmaceutical Sciences·Jurgen MenschPatrick Augustijns
Nov 26, 2010·Journal of Alzheimer's Disease : JAD·Saleta SierraJavier S Burgos
Nov 23, 2011·Pharmacological Reviews·Patrizia GazzerroMaurizio Bifulco
Jul 27, 2012·Journal of Pharmaceutical Sciences·Fatma Goksin BaharTeruko Imai
Oct 29, 2013·Cancer Chemotherapy and Pharmacology·Tamer A AhmedMarkos Leggas
Nov 26, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M O JacusC F Stewart
Feb 12, 2015·Clinical Pharmacology and Therapeutics·K E ParrishW F Elmquist
Jun 16, 2015·Nature Genetics·Kumarasamypet M MohankumarRichard J Gilbertson